When and how people recover after an intracerebral hemorrhage
Official title: Timing and Outcomes of Recovery After intraCerebral Hemorrhage
Run by Xuanwu Hospital, Beijing · NCT07166146 · Data updated 2026-11-12
This registry will collect detailed, long-term data on adults who have surgery for intracerebral hemorrhage to see if the timing and type of surgical treatment affect recovery and quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Xuanwu Hospital, Beijing Academic / other |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | June 4, 2025 |
| Main results expected | March 15, 2027 |
| Study ends | March 15, 2028 |
| Registry record updated | September 10, 2025 |
| Trial ID | NCT07166146 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–80 with an acute primary supratentorial intracerebral hemorrhage who undergo a surgical intervention and have baseline mRS ≤1 and NIHSS ≥6 or GCS 5–15 are ideal candidates.
✕Probably not a fit
Patients with secondary causes of intracerebral hemorrhage, irreversible coagulopathy, very limited life expectancy from other illnesses, or those not receiving surgery are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The TORCH registry is a prospective, observational cohort enrolling adults with acute, spontaneous supratentorial intracerebral hemorrhage who receive surgical treatment at Xuanwu Hospital. It will collect standardized, longitudinal data on clinical presentation, imaging (CT/CTA), surgical modality (including endoscopic evacuation, minimally invasive surgery with urokinase, and craniotomy), timing of intervention, and functional and quality-of-life outcomes. Eligibility includes age 18–80, baseline mRS ≤1, and defined severity thresholds (NIHSS ≥6 or GCS 5–15); patients with secondary causes of hemorrhage or irreversible coagulopathy are excluded. By comparing outcomes across interventions and timing, the registry aims to produce granular, real-world evidence to guide surgical decision-making.
Why it matters
Potential benefit: If successful, the registry could identify which surgical approaches and timing are linked to better recovery and quality of life, helping guide future treatment choices.
How similar studies have gone: Previous randomized and observational efforts of minimally invasive and endoscopic hematoma evacuation have shown mixed results—some reduce hematoma volume but have not consistently produced clear functional benefit—so comparative registry data remain valuable and relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject Age is ≥18 to ≤80 years * Subject with a Head CT/CTA that demonstrates an acute, spontaneous, primary, supratentorial ICH, assessed via standard of care techniques * Subject recieving a surgery intervention * Subject has a NIHSS score ≥ 6 or GCS score 5≤GCS≤15 * Subject has a baseline Modified Rankin Scale (mRS) Score ≤ 1 Exclusion Criteria: * Secondary intracerebral hemorrhage (with leading cause, e.g., Moyamoya disease, arteriovenous malformation, intracranial aneurysm, tumor, brain trauma) * Pre-stroke life expectancy \< 1 year for severe comorbidities (e.g., Progressive malignant tumor, severe chronic heart failure \[NYHA: III-IV\], severe chronic obstructive pulmonary disease \[III-IV\], chronic kidney disease requiring hemodialysis) * Patients with platelet count \< 100,000, INR \> 1.4, or an elevated PT or APTT (reversal of coumadin is permitted but the patient must not require coumadin during the acute hospitalization). Irreversible coagulopathy either due to medical condition or prior to randomization * Pregnant (positive pregnancy test) or lactating females (likelihood of altered coagulation function associated with the high estrogen/progesterone state) * Irreversibly impaired brainstem function (bilateral fixed, dilated pupils and extensor motor posturing), GCS less than or equal to 4
Where it's running
-
The Department of Neurosurgery, China International Neuroscience Institute, Xuanwu Hospital, Capital Medical University,
Beijing, China Recruiting
Study contacts
- Study coordinator: Tao Hong, MD
- Email: hongtao.edu@gmail.com
- Phone: +86-13810000653
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-assisted transcranial Doppler ultrasound to detect early brain bleeding
This will try to see if a quick transcranial Doppler ultrasound combined with artificial intelligence can detect intracerebral bleeding in adults with suspected acute stroke within 48 hours of symptom onset.
-
Care bundle to improve recovery after intracerebral haemorrhage
This trial will try a structured treatment package—rapid reversal of blood thinners when needed, early intensive blood pressure lowering, and treatment of fever and high blood sugar—to see if it improves 3‑month outcomes for adults with spontaneous intracerebral haemorrhage who arrive within 24 hours of symptom onset.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Smartphone-based EEG to detect hidden awareness in ICU patients with brain injuries
Researchers will test a smartphone-enabled EEG to see if it can reveal Cognitive Motor Dissociation in ICU patients who can’t show commands at bedside.
-
Chinese multicenter group studies spontaneous intracerebral hemorrhage in adults
This study tests how a large group of adults with spontaneous intracerebral hemorrhage (and a healthy control group) progress over time to understand outcomes and determinants of recovery.
-
Rapid Evacuation and Access of Cerebral Hemorrhage Registry: observing minimally invasive surgery outcomes
This registry collection tests how minimally invasive brain-bleed procedures work in real patients with acute spontaneous intracerebral hemorrhage.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.